These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7856275)

  • 41. [Recent molecular and pharmacologic aspects of ACE inhibitors].
    Köppel H; Eber B; Gasser R; Klein W
    Wien Med Wochenschr; 1995; 145(23):633-7. PubMed ID: 8578754
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Angiotensin converting enzyme inhibition in cardiovascular risk populations: a practical approach to identify the patient who will benefit most.
    Asselbergs FW; van Gilst WH
    Curr Opin Cardiol; 2007 Jul; 22(4):267-72. PubMed ID: 17556876
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Angiotensin-I converting enzyme].
    Nakai K; Syoh T; Hiramori K
    Nihon Rinsho; 1995 May; 53(5):1232-6. PubMed ID: 7602784
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials.
    Liu Y; Ma X; Zheng J; Jia J; Yan T
    BMC Nephrol; 2017 Jun; 18(1):206. PubMed ID: 28666408
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of the Renin-Angiotensin-Aldosterone System and Its Pharmacological Inhibitors in Cardiovascular Diseases: Complex and Critical Issues.
    Borghi C; ; Rossi F;
    High Blood Press Cardiovasc Prev; 2015 Dec; 22(4):429-44. PubMed ID: 26403596
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The current role of ACE-inhibitors for secondary prevention in cardiovascular disease; from pathogenesis to clinical practice.
    Voors AA; van Veldhuisen DJ; van Gilst WH
    Cardiovasc Drugs Ther; 2006 Feb; 20(1):69-73. PubMed ID: 16619108
    [No Abstract]   [Full Text] [Related]  

  • 47. ACE inhibitors and the arterial wall. Introduction.
    Frishman WH
    Postgrad Med; 2000 Oct; 108(5 Suppl):3. PubMed ID: 19667534
    [No Abstract]   [Full Text] [Related]  

  • 48. [Prospective trends in the study of the therapeutic action of angiotensin-converting enzyme inhibitors in cardiovascular diseases].
    Novikova LS; Arabidze GG
    Ter Arkh; 1990; 62(1):118-23. PubMed ID: 2159193
    [No Abstract]   [Full Text] [Related]  

  • 49. Ask the doctor. Recently, I read that the ACE inhibitor ramipril is very good at preventing heart problems, particularly in people with diabetes. I'm diabetic, and for years I have been on a different ACE inhibitor (lisinopril). Should I be taking ramipril instead?
    Lee TH
    Harv Heart Lett; 2001 Apr; 11(8):7-8. PubMed ID: 11343399
    [No Abstract]   [Full Text] [Related]  

  • 50. The emerging role of ACE inhibitors in diabetes: from theory to therapeutic management.
    Yudkin JS
    J Diabetes Complications; 1996; 10(3):129-32. PubMed ID: 8807456
    [No Abstract]   [Full Text] [Related]  

  • 51. Angiotensin-converting enzyme inhibitors for cardiovascular therapy: recent advances at the Tenth World Congress of Cardiology Washington DC, September 14-19, 1986.
    Opie LH
    Cardiovasc Drugs Ther; 1987; 1(1):111-2. PubMed ID: 2908699
    [No Abstract]   [Full Text] [Related]  

  • 52. Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril.
    Dinicolantonio JJ; Lavie CJ; O'Keefe JH
    Postgrad Med; 2013 Jul; 125(4):154-68. PubMed ID: 23933903
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Renin-angiotensin system modulation for treatment and prevention of cardiovascular diseases: toward an optimal therapeutic strategy.
    Giles TD
    Rev Cardiovasc Med; 2007; 8 Suppl 2():S14-21. PubMed ID: 17401312
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The chymase-angiotensin system in humans: biochemistry, molecular biology and potential role in cardiovascular diseases.
    Liao Y; Husain A
    Can J Cardiol; 1995 Aug; 11 Suppl F():13F-19F. PubMed ID: 7664213
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Of snakes and men: the evolution of ACE inhibitors.
    Bomback AS; Bove RM; Klemmer PJ
    J Renin Angiotensin Aldosterone Syst; 2007 Mar; 8(1):1-2. PubMed ID: 17487820
    [No Abstract]   [Full Text] [Related]  

  • 56. [Endothelium--a new target for a therapeutic action of angiotensin-converting enzyme inhibitors].
    Karpov IuA
    Ter Arkh; 2004; 76(6):94-6. PubMed ID: 15332589
    [No Abstract]   [Full Text] [Related]  

  • 57. Progression of cardiovascular damage: the role of renin-angiotensin system blockade.
    Probstfield JL; O'Brien KD
    Am J Cardiol; 2010 Jan; 105(1 Suppl):10A-20A. PubMed ID: 20102969
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The renin-angiotensin system--from Tigerstedt to Goldblatt to ACE inhibition and beyond.
    Atlas SA; Rosendorff C
    Mt Sinai J Med; 1998 Mar; 65(2):81-6. PubMed ID: 9520510
    [No Abstract]   [Full Text] [Related]  

  • 59. Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in preventive cardiology: which drug to use and what to expect in light of the ONTARGET trial.
    Cairns JA
    Pol Arch Med Wewn; 2008 Jun; 118(6):335-8. PubMed ID: 18619187
    [No Abstract]   [Full Text] [Related]  

  • 60. [Use of angiotensin-converting enzyme inhibitors in chronic cardiac insufficiency (documents of XVI-XXI congresses of European Cardiologic Society)].
    Martynov AI; Stepura OB; Gadzhiev AN; Ivanova SV; Tomaeva FE
    Klin Med (Mosk); 2001; 79(4):71-4. PubMed ID: 11496749
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.